CloudMD Software and Services Inc. (DOCRF)

[mrdecember123]

keep the good news coming- Buy, Hold, add at one's leisure here.

[StockpickerCAPC]

CloudMD to Participate in Upcoming Laurentian Bank and Bloom Burton & Co. Investor Conferences.

source
http://www.digitaljournal.com/pr/5027127

April 05, 2021

CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH), a healthcare technology company revolutionizing the delivery of care, is pleased to announce that the Company has been invited to participate in the upcoming Laurentian Bank Securities and Bloom Burton & Co. investor conferences.

Laurentian Bank Securities Annual Institutional Investor Conference (April 6-9, 2021)
Thursday April 8, 2021 at 12:45pm EST (9:45am PST) – Diversified Technology Track

Dr. Essam Hamza will be participating on a panel discussion titled, Digital Healthcare: Where To From Here?. Members of management will also be participating in one-on-one investor meetings.
Investors should contact a Laurentian Bank Securities representative for more information and to schedule one-on-one meetings with management.

Bloom Burton & Co. Annual Healthcare Investor Conference (April 20-21, 2021)
Tuesday April 20, 2021 at 3:00pm EST (12:00am PST) – Track 2
Dr. Essam Hamza will be presenting the Company and providing an update on the business via a webinar. Members of management will also be participating in one-on-one investor meetings during the conference.

For more information and to register for the event,
visit the Bloom Burton & Co.
https://www.meetmax.com/sched/event_71993/conference_register.html

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. By leveraging healthcare technology, the Company is building one, connected platform that addresses all points of a patient’s healthcare journey and provides better access to care and improved outcomes. Through CloudMD’s proprietary technology, the Company delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 7,000 psychiatrists, approximately 4,500 therapists and counsellors, approximately 4,000 psychologists, over 22,000 family physicians, over 34,000 medical specialists, over 1,500 allied health professionals, over 500 clinics, and over 2.5 million individuals across North America. CloudMD’s Enterprise Health Solutions Division includes one of the top 4 Employee Assistance Programs in Canada and offers one comprehensive, digitally connected platform for corporations, insurers and advisors to better manage the health and wellness of their employees and customers.
For more information visit:
https://cloudmd.ca/

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
Vice President, Investor Relations
Email: [e-mail]
Tel: [phone]

[StockpickerCAPC]

Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing.

source
http://www.digitaljournal.com/pr/5020460

March 29, 2021

Life Sciences Investor Forum today announced that the presentations from the March 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com.

This virtual event showcased live company presentations and interactive discussions focused on the life sciences industry. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

REGISTER OR LOGIN AT:
https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Post%20PR&utm_medium=Press%20Release&utm_campaign=0325LSIF

March 25th Presenting Companies:
MagicMed Industries Inc. Ticker Pending
Sernova Corp. OTCQB: SEOVF | TSX-V: SVA
VolitionRx Limited NYSE AMERICAN: VNRX
Skylight Health Group Inc. OTCQX: SHGFF | TSX-V:SHG
Else Nutrition Holdings Inc. OTCQX: BABYF | TSX-V: BABY
Cardiol Therapeutics Inc. OTCQX: CRTPF | TSX: CRDL
EarthRenew Inc. OTCQB: VVIVF | CSE: ERTH
Avicanna Inc. OTCQX: AVCNF | TSX: AVCN
Orexo AB OTCQX: ORXOY | STO: ORX
CloudMD Software & Services Inc. Pink: DOCRF | TSX-V: DOC

To facilitate investor relations scheduling and for more information about the program, please visit
https://www.lifesciencesinvestorforum.com/

About Life Sciences Investor Forum
Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.

A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

CONTACT
Life Sciences Investor Forum
John M. Viglotti
SVP Corporate Services, Investor Access
[phone]
[e-mail]

[StockpickerCAPC]

CloudMD Announces Closing of IDYA4 Acquisition and North American roll out of Substance Use Disorder Platform to Address Growing Addiction Crisis.

source
http://www.digitaljournal.com/pr/5014543

March 23, 2021

- The COVID-19 pandemic has resulted in a significant increase in substance use across North America.
- IDYA4’s Real Time Intervention Platform for Substance Use Disorder is used across 38 states in the United States.
- The platform shares information within the bounds of policies and laws like The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and the Criminal Justice Information Sharing (“CJIS Policy”) to view individual's historical data to help them get the right treatment.
- Provides real time analysis on the needs of the individuals to ensure successful rehabilitation.
- The platform enables access to healthcare data for the successful treatment and rehabilitation in compliance with the Office of the National Coordinator for Health Information Technology’s (“ONC”) interoperability rule.
- CloudMD is focused on expanding the platform further across the United States and in Canada.

CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH), a healthcare technology company revolutionizing the delivery of care, is pleased to announce that it has closed the acquisition of IDYA4, a leading health technology company focused on data interoperability and cybersecurity based in the United States.

Built on over 20 years of experience, the IDYA4 team has been at the forefront of the development of information sharing and interoperability solutions across all 50 states for clients including the US Department of Justice, the US Department of Homeland Security, US Health and Human Services, and National Intelligence.

IDYA4 is the technology backbone of CloudMD’s integration of its healthcare solutions providing one, digitally connected, patient-focused platform. Initial stages of the integration are well underway and IDYA4 is already integrated with Snapclarity, Livecare and iMD Health. The Company will be deploying a fully unified product offering to partners and enterprise clients within the next few months. The combined technology will also be valuable as CloudMD continues to emphasize patient engagement through connected technology, healthcare portals, telehealth applications, and wearable devices.

Real Time Intervention Platform for Substance Use Disorder.
Upon closing of the acquisition, the Company can now focus on the continued expansion of IDYA4’s Real Time Intervention Platform (“RTIP”) for Substance Use Disorder (“SUD”) across North America to help and support the growing addiction crisis.

The COVID-19 pandemic has affected communities across North America and the number of Substance Use Disorders is on a rise resulting in fatal overdoses. Over 81,000 drug overdose deaths occurred in the United States in the 12 months ending in May 2020, the highest number of overdose deaths ever recorded in a 12-month period according to recent provisional data from the Centers for Disease Control and Prevention (“CDC”).
https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html

Canada is facing similar challenges where between April and June 2020, there were over 1,628 opioid toxicity-related deaths, resulting in a startling 54% increase from the year before. Nearly 97% of these deaths were found to be accidental.
https://thefulcrum.ca/features/the-epidemic-within-a-pandemic-opioid-overdoses-continue-to-make-an-impact-during-covid-19/

In mid-August 2020, the CDC revealed the results of a survey conducted in late June 2020 that opens a window into just how serious the psychological and emotional impact of the Coronavirus pandemic is for Americans. The survey shows that reports of anxiety disorder symptoms were about three times those reported in the second quarter of 2019 (25.5% versus 8.1%), and depressive disorder was about four times that reported in Q2 2019 (24.3% versus 6.5%). CDC also said 13.3% of respondents reported starting or increasing substance abuse (including drugs and alcohol). In addition, more than twice as many respondents reported serious consideration of suicide in the previous 30 days than did adults in the US in 2018, referring to the previous 12 months (10.7% versus 4.3%).

The RTIP for SUD is an innovative, health data integration and security technology solution leveraging various information sharing standards and is already operational across 38 states and local agencies to address the opioids crisis. Some of these agencies include Bergen County Prosecutors Office, New Jersey, Passaic County Prosecutors Office New Jersey, and the Executive office Public Safety and Security at Commonwealth of Massachusetts.

These state level agencies have received funding from the US Department of Justice, CDC, Center for Medicaid Services (“CMS”) and the Office of the National Coordinator for Health Information Technology (“ONC”) to implement RTIP in keeping their communities healthier and safer. The Company plans on expanding and scaling the platform further across the United States and in Canada.

RTIP for SUD enables broader collaboration among behavioral health, human services, and justice professionals to share information within the bounds of policies and laws like The Health Insurance Portability and Accountability Act of 1996 (HIPAA), Criminal Justice Information Sharing and the ONC’s Interoperability Rule to enable access to patient health data and to view individual's historical data to help them get the right treatment and services for successful rehabilitation process. The platform provides real time analysis on the needs of the individuals to ensure successful rehabilitation.

Dr. Amit Mathur, President of CloudMD, “We are very excited to close the acquisition of IDYA4 as it provides us with the technology backbone for our integrated health services platform which connects all our healthtech solutions into one seamless experience. Equally exciting is our ability to scale across North America with programs like the Substance Use Disorder platform and already established partnerships at the highest level of Government agencies. We will use the RTIP platform to provide similar solutions in Canada to assist in addressing the enormous issue of opioid and substance use made even worse as a result of the COVID-19 pandemic.”

IDYA4 generated approximately US$4.4 million in revenues with earnings before interest, taxes, depreciation and amortization (“EBITDA”) margins exceeding 31% over the 12-month period ending December 31, 2020. Since announcing the binding agreement in December 2020, IDYA4 has launched a number of national programs and closed various new contracts that will generate US$1.5 million.

From IDYA4’s currently commercialized products, the Company expects IDYA4 to achieve an annual pro forma revenue growth rate greater than 45%, calculated based on expected revenue from currently committed and high probability contracts forecasted to generate annual gross revenue greater than US$6 million and US$8.5 million in calendar years 2021 and 2022, respectively. A total of 30 per cent of the total consideration for the acquisition amounting to $4.44-million (U.S.) is based on two performance-based earnouts, 15 per cent each, that are contingent on meeting these forecasted revenue targets.

Terms of Agreement
In consideration for the purchase of 100% of the issued and outstanding IDYA4 securities, CloudMD has paid US$14.8 million as follows: (i) US$3.7 million in cash, subject to a working capital adjustment; (ii) US$6.66 million in common shares of the Company; and (iii) a performance based earnout. See press release dated December 17, 2020 for full terms.

About IDYA4
IDYA4 is a health data integration and a data security company working to transform businesses through improved data management, security and integration, as well as protection against today’s ever-changing cyber threats. IDYA4 works to achieve the best possible outcomes for its clients while striving to build safer and healthier communities worldwide.
For more information visit
https://idya4.com/

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SaaS-based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 7,000 psychiatrists, approximately 4,500 therapists and counsellors, approximately 4,000 psychologists, over 22,000 family physicians, over 34,000 medical specialists, over 1,500 allied health professionals, over 500 clinics, and 8 million patient charts across North America. CloudMD’s Enterprise Health Solutions Division includes one of the top 4 Employee Assistance Programs in Canada and offers one comprehensive, digitally connected platform for corporations, insurers and advisors to better manage the health and wellness of their employees and customers.
For more information visit:
https://cloudmd.ca/

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[StockpickerCAPC]

CloudMD Announces Rapid Growth of Enterprise Health Solutions Division.

source
http://www.digitaljournal.com/pr/5010255

March 18, 2021

- Driving strong organic growth through cross-selling and integrated product offerings
- Identified over $500,000 in near-term operational synergies through the initial phase of integration
- Secured large corporate customer contract for new integrated health and wellness platform launching in April 2021
- CloudMD is one of a few companies in North America to provide one, centralized, whole-person solution for employers to better manage the health and wellness of employees
- Anticipated annual pro forma revenue growth rate of over 20% with healthy gross margins exceeding 50%.

CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH), a healthcare technology company revolutionizing the delivery of care, is pleased to provide an update on its Enterprise Health Solutions (“EHS”) Division. Since launching the EHS Division, CloudMD has seen significant organic growth and integration synergies across the platform.

Organic Growth
The EHS Division offers one of the first centralized and connected platforms of health and wellness solutions for employers as part of their benefits programs. These solutions include employee assistance programs, mental health support, physician/allied health services, professional referrals, personalized healthcare navigation, speciality drug consultation, health literacy and education and other services aimed at prevention and early intervention of health concerns.

CloudMD closed the majority of its EHS business acquisitions in January 2021 and since then, the Company has secured $5 million in new, multi-year customer contracts for mental and physical health solutions. These recurring revenue contracts include organizations of all sizes including large corporate clients like Medavie Blue Cross. Additionally, the EHS Division has identified operational synergies by centralizing marketing, technology and finance functions, enabling a shared services approach with annual cost savings exceeding $500,000. The EHS Division is executing on market share growth, margin expansion, cross-selling and integration of capabilities. The Company expects to continue driving additional profitable, organic growth across the entire division. CloudMD anticipates the continued growth of the EHS Division, with annual pro forma revenue growth rate of over 20% and healthy gross margins exceeding 50%.

Integrated Health Services Platform
In April 2021, the Company will be launching its EHS fully-integrated, proprietary health services platform with a large corporate customer, serving over 10,000 employees across Canada. Employees will be triaged and assessed using CloudMD clinical tools followed by appropriate service activation with navigation assistance to ensure the individual has the optimal outcome and continuity of care. Employers will have aggregate data to ensure the right benefit plans are being used for the right health issues. This transformational platform is revolutionizing the way employees access healthcare by providing one seamless patient experience, including personalized care plans, triage and navigation, and full support through their treatment journey. Organizations can use this platform to ensure inclusivity and diversity for mental and physical health issues. This approach provides better access to care, improved patient outcomes, faster access to treatment and improved return to work outcomes.

Scalability and Growth
CloudMD’s network includes over 7,000 psychiatrists, approximately 4,500 therapists and counsellors, over 4,000 psychologists, over 22,000 family physicians, approximately 34,000 medical specialists, over 1,500 allied health professionals and a dedicated research team across North America. The size of this network, leveraged by technology, provides the foundation for scalability and growth across North America and globally.
Rising global health concerns surrounding mental and physical issues have created new needs for providing more efficient, integrated and accessible care options. Employers, insurers and advisors can entrust CloudMD’s integrated health services platform to provide employees with whole-person, personalized care through a complete portfolio of healthcare services that are required in supporting improved health and wellness. The omni-channel approach to navigation and activation of services can be accessed virtually through the web, mobile and telephone, ensuring appropriate care and optimized value.

Karen Adams, Global Head, EHS Division commented, “We are very excited with the performance and growth of the EHS Division since we launched in January 2021. The biggest challenge for payors is having to find multiple, siloed solutions to service their employee’s needs. Our EHS mission is to help businesses and individuals thrive by reducing the need of multiple employer benefits products, and instead create one seamless, connected platform. We have built one of the industry’s first employee benefits platforms that integrates assessment, triage, navigation, care advocacy, educational content, payments and provider connectivity. This solution supports all paths to physical and mental healthcare prevention and treatment while using social and environmental needs currently supported through traditional EAP as the anchor. We feel strongly that this centralized platform will enable deeper member engagement, support inclusivity and diversity and provide for more positive healthcare outcomes.”

In addition, CloudMD announces it has engaged Native Ads, Inc. to provide strategic digital media services, marketing, and data analytics services. The Company has agreed to pay Native Ads $300,000 in consideration for the Services to be provided. Native Ads will not receive any securities of the Company as compensation for the Services.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 7,000 psychiatrists, approximately 4,500 therapists and counsellors, approximately 4,000 psychologists, over 22,000 family physicians, over 34,000 medical specialists, over 1,500 allied health professionals, over 500 clinics, and 8 million patient charts across North America. CloudMD’s Enterprise Health Solutions Division includes one of the top 4 Employee Assistance Programs in Canada and offers one comprehensive, digitally connected platform for corporations, insurers and advisors to better manage the health and wellness of their employees and customers.
For more information visit:
https://cloudmd.ca/

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD" Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[StockpickerCAPC]

CloudMD Announces Closing of $8.2 Million Over-Allotment Option.

soure
https://finance.yahoo.com/news/cloudmd-announces-closing-8-2-140400411.html

Fri, March 12, 2021, 3:04 PM

CloudMD Software & Services Inc., a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that it has completed the sale of an additional 3,060,000 common shares of the Company at the price of $ Canada 2.70 per Share for aggregate gross proceeds to the Company of $8,262,000. The Shares were issued pursuant to the full exercise of the over-allotment option granted to Canaccord Genuity Corp., Beacon Securities Limited and Echelon Wealth Partners Inc. on behalf of a syndicate of underwriters including Laurentian Bank Securities Inc. and Mackie Research Capital Corporation in connection with the Company’s bought deal short form prospectus offerin.

The Company issued the Underwriters an additional 214,200 broker warrants. Each Broker Warrant is exercisable to acquire one common share of the Company at the exercise price of $2.70 per common share for a period of 24 months from the closing date of the Offering.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.
For more information visit:
https://investors.cloudmd.ca/

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
Vice President, Investor Relations
Email: [e-mail]
investors.cloudmd.ca

[StockpickerCAPC]

CloudMD Announces Closing of $55 Million Bought Deal Financing.

source
http://www.digitaljournal.com/pr/4999693

March 09, 2021
CloudMD Software & Service, a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that it has closed its previously announced short form prospectus offering, on a bought deal basis. The Company issued a total of 18,500,000 common shares at the price of $2.70 per Share for aggregate gross proceeds to the Company of $49,950,000. The Offering was led by Canaccord Genuity Corp., Beacon Securities Limited and Echelon Wealth Partners Inc. on behalf of a syndicate of underwriters including Laurentian Bank Securities Inc. and Mackie Research Capital Corporation.

In addition, 1,900,000 Shares were purchased by the Underwriters from Essam Hamza and Kanchan Thindal at the Offering Price for aggregate gross proceeds to the Selling Shareholders of $5,130,000.

The Company issued the Underwriters an aggregate of 1,295,000 broker warrants. Each Broker Warrant is exercisable to acquire one common share of the Company at the exercise price of $2.70 per common share for a period of 24 months from the closing date of the Offering.

Essam Hamza, CEO of CloudMD commented, “I’m very proud of the team for closing another bought deal financing, which allows us to continue executing on our strategic M&A plan. CloudMD has seen significant growth over the last year and we remain committed to our vision of disrupting the delivery of healthcare, with a whole-person, patient-centric approach to care. Our focus remains on seamlessly integrating our platform of healthtech solutions to provide one, centralized product offering for our patients, providers and clients. We have seen some early successes on the integration which is already driving organic growth. Upon closing of the financing, we have strong balance sheet with approximately $100 million in cash, leaving us approximately $60 million following the closing of previously announced acquisitions. We are well-positioned to continue delivering growth while we actively review both organic and acquisitive growth opportunities. Thank you to our key stakeholders, syndicate partners and supportive shareholders for the confidence in our team and vision moving forward.”

CloudMD intends to use the proceeds of the Offering for strategic M&A activities.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America. For more information visit: investors.cloudmd.ca
ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
Vice President, Investor Relations
Email: [e-mail]
investors.cloudmd.ca

[StockpickerCAPC]

Medavie Blue Cross partners with Medical Confidence to create new way to support Canadians on disability waiting for a specialist.

source
https://finance.yahoo.com/news/prodigy-technovations-announces-innovative-100baset1-060000829.html

Tue, March 2, 2021, 12:00 PM

Company partners with Medical Confidence, a CloudMD company, to provide plan members on disability with timely access to care and treatment.

Medavie Blue Cross
http://www.medaviebc.ca/
has partnered with Medical Confidence
https://www.medicalconfidence.com/about-us/
(part of CloudMD (TSXV: DOC)) to begin providing select plan members on disability with the opportunity to access MedExcellence
https://www.medicalconfidence.com/medexcellence/
– a personalized healthcare navigation service that can reduce the wait time to see a specialist.

Many Canadians experience long wait times to receive treatment from a specialist. From referral by a general practitioner to consultation and treatment by a specialist, the average wait time for Canadians in 2020 was 22.6 weeks.
https://www.fraserinstitute.org/sites/default/files/waiting-your-turn-2020.pdf
The pandemic, and the associated pressure placed on Canada's healthcare system, has caused these wait times to increase further.1

"From what we are seeing, Canadians may now need to wait even longer to get an appointment with a specialist," says Rebecca Smith, Director, Group Life and Disability Services, Medavie Blue Cross. "We are delighted to offer this opportunity to connect those on disability with a specialist sooner. We believe this will help many of our plan members in seeing the best possible health outcomes and potentially seeing a quicker recovery from their disability."

MedExcellence works in alignment with the Canada Health Act and provincial healthcare systems to get Canadians on disability, who are waiting for an appointment, earlier access to a specialist for their condition. Medical Confidence also works with eligible individuals to help them understand their health-related circumstance and become actively engaged in decisions regarding their treatment and recovery.

"The majority of Canadians do not know what to do or where to turn when faced with a serious medical condition," says Angela Johnson, President of Medical Confidence. "The ever-increasing wait times have become the norm, made worse by COVID-19's impact on our healthcare system We are delighted to be teaming up with Medavie Blue Cross. Through our innovative navigation platform, we will provide Medavie plan members a customized and caring approach to obtaining the right treatment at the right time. The result is reduced wait times and improved outcomes for patients and their physicians."

Benefits of MedExcellence:
https://www.medicalconfidence.com/medexcellence/
- The service leverages a national network of over 27,000 specialists.

- People who have used this service have been able to access a specialist 220 days sooner on average.

- Disability insurers who have used the program have seen a six-month reduction in duration of disability, on average.

- Improved employee satisfaction – reported by 75% of clients.

Medavie Blue Cross disability case managers will work with plan members on disability to access this service in appropriate circumstances based on referral criteria.

About Medavie Blue Cross
Medavie Blue Cross is a premier all-in-one carrier that provides health, dental, travel, life and disability benefits, and administers various federal and provincial government-sponsored health programs. Together with Medavie Health Services, we are part of Medavie, a health solutions partner committed to improving the wellbeing of Canadians.

We are one of Canada's Most Admired Corporate Cultures and recognized as an Imagine Canada Caring Company. As a not-for-profit organization, we are proud to commit an annual social dividend to the Medavie Health Foundation to support programs and initiatives aimed at addressing some of our country's most pressing physical and mental health care challenges.

About Medical Confidence
Medical Confidence is a pioneer healthcare navigation platform that reduces healthcare costs through achieving better health outcomes. Working in alignment with the Canadian Health Act, Medical Confidence removes the numerous causes for delay in our healthcare system to achieve optimal access to care. Leveraging its unmatched national network of over 27,000 specialists, it connects healthcare consumers to the care they need, sooner, leading to earlier recovery. Its health outcomes are measurable and demonstrate reductions in costs associated with absenteeism and presenteeism. Medical Confidence's corporate clients report that its services have reduced their absence costs by 20%.
For more information on Medical Confidence, visit:
https://www.medicalconfidence.com/

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.
For more information on CloudMD, visit:
https://cloudmd.ca/

[StockpickerCAPC]

CloudMD Signs Definitive Agreement to Acquire IDYA4, a North American Leader in Healthcare Data Integration and Cybersecurity.

source
http://www.digitaljournal.com/pr/4981188

Feb. 22, 2021

- Innovative, health data integration and security technology solution leveraging various information sharing standards supported by the U.S. Department of Justice, the U.S. Department of Homeland Security, U.S Health and Human Services and currently in use by various Government agencies at the Federal, State and Local level.

- Solution is CloudMD’s technology backbone for combining its services and continued growth through implementing new technology applications, healthtech solutions and wearable devices.

- Immediately synergistic and accretive, with approximately US$4.4M revenue in 2020 with EBITDA margins of 31% with a strong revenue pipeline and growth opportunities.

- With IDYA4’s currently commercialized products, expected annual revenue growth rate is over 45%.

- Since announcing the binding agreement in December 2020, IDYA4 has launched a number of national programs and closed various new contracts that will generate US$1.5 Million.

CloudMD Software & Services Inc., a healthcare technology company revolutionizing the delivery of care, is pleased to announce that it has signed a definitive agreement to acquire IDYA4, a leading health technology company focused on data interoperability and cybersecurity based in the United States. Since announcing the binding agreement in December 2020, IDYA4 has closed various new contracts and waiting task orders to be finalized for approximately $1.5Million (USD).

Focused on the health and wellness sector, IDYA4 has built a proprietary technology platform that provides improvements in data access, management, security and integration, as well as actively screening and protecting against today’s ever-changing cyber threats. Built on over 20 years of experience, the IDYA4 team has been at the forefront of the development of information sharing and interoperability solutions across all 50 states for clients including, the U.S. Department of Justice, the U.S. Department of Homeland Security, U.S Health and Human Services, and National Intelligence.

IDYA4’s Real Time intervention platform (RTIP) is the technology backbone of CloudMD’s integration of its healthcare solutions providing one, digitally connected, patient focused platform. Initial stages of the integration are well underway, and the Company will be deploying the unified product offering to partners and enterprise clients within a few months. The combined technology will also be valuable as CloudMD continues to emphasize patient engagement through connected technology, healthcare portals, telehealth applications, and wearable devices.

Various RTIP modules have been operational for last 15 years in the health, human services, homeland security and Public safety to enable information sharing and interoperability. The same RTIP is now also operational in Bergen County, New Jersey to address the opioid overdose crisis. The RTIP platform is connecting public health, social services, and public safety systems to address the real time needs of the individuals who have overdosed or may be at risk. This effort is funded by the U.S. Department of Justice and a local Public Safety agency.

IDYA4 has also launched the First Responders
Health Wellness Network
https://www.prweb.com/releases/idya4_s_new_health_and_wellness_network_to_address_behavioral_health_challenges/prweb17593829.htm
to address the Behavioral Health issues including Substance Use Disorder among the First Responders (Law Enforcement, Fire and Emergency Management Services). The Health and Wellness Network will provide an end-to-end solution to the individuals who need help at any hour of the day. This network is developed on IDYA4’s RTIP allowing the individual to access the platform through their mobile device, desktop or laptop to check their health and wellness on a daily basis via this application developed by Behavioral Health experts. This program already includes CloudMD solutions, Snapclarity, Livecare and iMD and the company is in its initial phase of implementing a proof of concept that is supported by the Key Public Safety Associations and funded by the U.S. Department of Justice.

IDYA4’s team is now providing subject matter expertise to address the interoperability issues among the Public Safety and Public Health agencies across the U.S. to coordinate efforts in addressing National issues like COVID-19 and the opioid crisis. This key initiative is supported by the U.S Department of Homeland Security, State and Local Public Safety and Public Health agencies across the nation. IDYA4 has been engaged to provide advice to the US Federal agencies, State and local government, and National associations engaged in addressing the issues that North America faces around the opioid crisis. As part of this advisory, IDYA4 will be hosting multiple seminars to discuss how Public/Private leaders can come together to address the opioid crisis that American communities face.

CloudMD is fully committed to the privacy and security of patient data, and this integrated health data platform is both Health Insurance Portability and Accountability Act (HIPAA) compliant and is enabled for continuous monitoring to ensure the protection and privacy of sensitive data. The platform has been architected to support U.S. and International security standards like the National Institute of Standards and Technology (NIST) Cybersecurity Framework to address internal and external cyber threats.

IDYA4 generated approximately US$ 4.4 million in revenues with earnings before interest, taxes, depreciation and amortization (EBITDA) margins exceeding 31% over the 12 month period ending December 31, 2020. Upon closing, the acquisition of IDYA4 will be immediately accretive to CloudMD with synergies the Company believes will drive further revenue and increased EBITDA margin through cost savings achieved through the scaling of operations and by tapping into CloudMD's health technology solutions that will be added to IDYA4’s current product portfolio. From IDYA4’s currently commercialized products, the Company expects to achieve an annual revenue growth rate greater than 45%, calculated based on expected revenue from currently committed and/or high probability contracts forecasted to generate annual gross revenue greater than US$6M and US$8.5M in calendar years 2021 and 2022, respectively. A total of 30% of the total consideration for the acquisition amounting to US$4.44 million is based on two performance based earnouts, 15% each, that are contingent on meeting these forecasted revenue targets.

Terms of Agreement
In consideration for the purchase of 100% of the issued and outstanding IDYA4 Securities, CloudMD has agreed to pay aggregate consideration of US$14.8 million payable as follows: (i) US$ 3.7 million in cash, subject to a working capital adjustment; (ii) US$ 6.66 million in common shares of the Company; and (iii) a performance based earnout.
The acquisition is subject to customary closing conditions, including the receipt of TSX Venture Exchange approval.

About IDYA4
IDYA4 is a health data integration and a data security company working to transform businesses through improved data management, security and integration, as well as protection against today’s ever-changing cyber threats. IDYA4 works to achieve the best possible outcomes for its clients while striving to build safer and healthier communities worldwide.
For more information visit:
https://idya4.com/

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.
For more information visit:
https://cloudmd.ca/

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[StockpickerCAPC]

CloudMD Increases Previously Announced Bought Deal Public Offering to $55 Million.

source
https://finance.yahoo.com/news/trez-capital-senior-mortgage-investment-010000207.html

Wed, February 17, 2021, 4:50 PM

CloudMD Software & Services Inc. (TSXV: DOC) (OTCQB: DOCRF), a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has entered into an amendment (the "Amendment") to the previously announced engagement agreement with Canaccord Genuity Corp. Beacon Securities Limited and Echelon Wealth Partners Inc., on behalf of a syndicate of Underwriters. The Underwriters have agreed to increase the size of the previously announced bought deal financing. Pursuant to the Amendment, the Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 20,400,000 common shares at a price of $2.70 per Share for aggregate gross proceeds of approximately $55 million. Of the aggregate 20,400,000 Shares being offered, 18,500,000 Shares will be issued from treasury by CloudMD for gross proceeds of approximately $50 million to the Company, and an aggregate of 1,900,000 Shares will be offered by Essam Hamza and Kanchan Thindal for aggregate gross proceeds to the Selling Shareholders of $5,130,000.

The Company has granted the Underwriter an option to purchase up to an additional 3,060,000 Shares at a price of $2.70 per Share, exercisable at any time, for a period of 30 days after and including the Closing Date, which would result in additional proceeds of $8.3 million.

The Shares will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on March 9, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange ("TSXV") and the applicable securities regulatory authorities.

The Company will use best efforts to obtain the necessary approvals to list the Shares on the TSXV.

CloudMD intends to use the net proceeds of the Offering for strategic M&A activities, working capital and general corporate purposes.

[StockpickerCAPC]

CloudMD Announces $45 Million Bought Deal Public Offering.

source
https://finance.yahoo.com/news/kraft-heinz-canada-announces-chief-153000329.html

Tue, February 16, 2021, 10:32 PM

CloudMD Software & Services Inc., a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has entered into an agreement with Canaccord Genuity Corp., Beacon Securities Limited and Echelon Wealth Partners Inc, on behalf of a syndicate of Underwriters. The Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 16,667,000 common shares at a price of $2.70 per Share for aggregate gross proceeds to the Company of approximately $45 million.

The Company has granted the Underwriter an option (the "Over-Allotment Option") to purchase up to an additional 2,500,050 Shares at a price of $2.70 per Share, exercisable at any time, for a period of 30 days after and including the Closing Date, which would result in additional proceeds of $6.8 million.

The Shares will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on March 9, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange ("TSXV") and the applicable securities regulatory authorities.

The Company will use best efforts to obtain the necessary approvals to list the Shares on the TSXV.

CloudMD intends to use the net proceeds of the Offering for strategic M&A activities, working capital and general corporate purposes.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America. For more information visit: investors.cloudmd.ca

ON BEHALF OF THE BOARD OF DIRECTORS
"Dr. Essam Hamza, MD"
Chief Executive Officer

[StockpickerCAPC]

CloudMD to Acquire VisionPros, a Rapidly Growing Digital Eyecare Platform with a Robust Suite of Digital Vision Care Tools.

source
http://www.digitaljournal.com/pr/4975297

VANCOUVER, British Columbia, Feb. 16, 2021

- VisionPros is headed by leading minds in the industry – including the pioneer of the first online vision test platform launched in the United States.

- VisionPros is a vertically integrated eyecare platform with almost 1 million unique customer accounts in North America.

- Unique subscription model with flexible monthly options; currently 18% of customer base on VisionPros.com subscribed and growing.

- Planned launch of innovative, best-in-class digital vision test technology embedded into e-commerce platform in 2021.

- Highly scalable business model, synergistic to CloudMD’s technology stack with significant cross-selling opportunities.

- Increases CloudMD’s annual revenue run rate to over $85 million.

CloudMD Software & Services Inc., a telehealth company revolutionizing the delivery of healthcare to patients, is excited to announce that it has signed a binding term sheet to acquire VisionPros, a vertically integrated digital eyewear platform that has serviced almost 1 million unique customers across North America.

VisionPros conveniently delivers contact lenses and glasses right to their customer’s door, anywhere in North America, at a fraction of the cost of traditional retail optical stores. The highly scalable business model includes a rapidly growing, high margin e-commerce platform, subscription business and innovative suite of digital vision care tools. VisionPros offers a unique subscription offering, with flexible monthly billing options, as well as some of the lowest prices in North America. The multi-disciplinary platform also includes a brick-and-mortar clinic, online/in-person dispensary and a lens laboratory that manufactures and distributes lenses to eyecare partners for their own affordable KIND eyewear line.

VisionPros was founded by Dr. Jessy Manhas and is led by a team of eye doctors committed to providing patient-focused vision care, and empowering practitioners through its disruptive tele-optometry technology. VisionPros’ CEO, Dr. Steven Lee, is a pioneer of the online vision tests in the market and developed the first online vision test platform which remains the current standard in North America. Subsequently, Dr. Lee developed, patented and is launching a new best-in-class, advanced technology that will deliver the safest online vision tests. This technology is designed to ensure a significantly higher level of accuracy and authentication of scripts. As part of VisionPros’ commitment to global eye health, the company has contributed to the Eyes for the World charity organization, founded by the principals of VisionPros and dedicated to restoring sight through glasses or surgery and to prevent blindness around the world. Amongst its contributions, Eyes for the World, has helped fund the construction and operation of two eye hospitals – one in India and one in Jamaica.

VisionPros’ digital platform shares many synergies with CloudMD’s existing platform and provides significant opportunities for cross-selling and integration. The e-commerce platform gives CloudMD direct access to almost 1 million unique customer accounts and further secures the Company’s footprint across North America. VisionPros’ revenue for calendar year 2020 surpassed $22 million with an adjusted earnings before interest, tax depreciation and amortization (“Adjusted EBITDA”) margin exceeding 10%.

Dr. Essam Hamza, CEO of CloudMD commented, “This is a significant acquisition for our business, which not only adds meaningful high margin revenue, but also provides us with an established e-commerce platform and almost 1 million customer accounts. VisionPros’ disruptive tele-optometry platform aligns with our vision of providing patient-focused, whole-person care and will allow us to leverage a number of our technologies and integrate our solutions into one seamless patient experience.”

Dr. Steven Lee, CEO of VisionPros commented, “We are extremely excited to partner with CloudMD and their physician led team. They share our commitment to providing a patient-centric approach that empowers physicians and engages patients. Our shared vision and combined resources are valuable for us as we look to undertake our aggressive growth strategy. There are obvious synergies across both health-tech platforms, and we look forward to leveraging those synergies to revolutionize the current system and build a North American leader in healthcare delivery.”

Terms of Acquisition
In consideration for the purchase of 100% of the outstanding securities of VisionPros, CloudMD has agreed to pay shareholders of VisionPros (i) $30 million in cash, subject to a working capital adjustment; (ii) $30 million in common shares of the Company at a deemed price by calculating the volume-weighted average trading price of the Company's common shares for the 10 trading days prior to the execution of the binding term sheet; and (iii) a performance-based earnout of up to $40 million, which is payable in cash or common shares of the Company, at the discretion of CloudMD at the time of the earn out. The common shares will be subject to certain contractual restrictions on trading for a period of 18 months from the date of issuance. Additionally, the Company will pay a 5% finder’s fee to an arm’s length party in accordance with TSX Venture Exchange policy.
The acquisition is subject to customary closing conditions, including the execution of a definitive acquisition agreement and receipt of TSX Venture Exchange approval.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.
For more information visit:
https://investors.cloudmd.ca/

About VisionPros
VisionPros is a Canadian-based online eyecare platform providing contact lenses and eyeglasses to customers across North America. The company sells contact lenses and glasses through a number of websites,
including:
https://www.visionpros.com/
and
https://www.contactlensescanada.com/

VisionPros offers customers all of the leading brands of contact lenses and has its own line of eyeglasses and sunglasses called KIND Eyewear. A doctor-led company, VisionPros has developed and will soon launch an innovative, disruptive online vision test that uniquely ensures the accuracy and authentication of scripts unseen before with current existing online vision tests. For over 10 years, VisionPros has donated funding, equipment and medical personnel to bring the gift of sight to people in need in underdeveloped countries. For more information on VisionPros,
please visit:
https://www.visionpros.com/

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[StockpickerCAPC]

CloudMD Closes Acquisition of West Mississauga Medical Clinic with 8 Family Doctors, 4 Specialists Serving Over 100,000 Patients.

source
http://www.digitaljournal.com/pr/4969382

Feb. 09, 2021

CloudMD Software & Services Inc., a telemedicine company revolutionizing the delivery of healthcare to patients, is pleased to announce that it has closed the previously announced acquisition to acquire a majority interest (51%) in West Mississauga Medical Ltd., a comprehensive family medicine and specialist medical clinic with 8 family doctors and 4 specialists serving over 100,000 patients.

West Mississauga Medical is a well-established medical clinic located on the border of Brampton, Mississauga and Milton in a high growth area. The clinic has served the community for over 16 years and remained open throughout the COVID-19 pandemic seeing patients via telemedicine and in-person. The acquisition is part of CloudMD’s national growth strategy which includes having well established brick and mortar clinic partners in major provinces. These clinics ultimately provide a strong, centralized patient base and footprint across the country. West Mississauga Medical will be integrated into the CloudMD EMR platform and its network of doctors and specialists will immediately start servicing CloudMD’s registered users and patients in Ontario.

Terms of Agreement
In consideration for the purchase of 51% of the outstanding securities of West Mississauga Medical, CloudMD has paid Shareholders aggregate consideration of C$200,000 payable as up to C$140,000 in cash and C$60,000 in shares of the Company. All shares issued pursuant to the acquisition are priced at the ten-day volume weighted trading price of the Company shares for the 10 trading days prior to the execution of the definitive agreement (see press release dated August 13, 2020).

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[StockpickerCAPC]

Kinduct Technologies and iMD Health Global announce partnership to place credible health rehabilitation and wellness resources into the hands of therapists and patients across North America.

source
https://www.kinduct.com/news/imd-health-global-partnership/
Halifax, Nova Scotia - February 8, 2021

Kinduct Technologies (Kinduct) is pleased to announce an important partnership with iMD Health Global (a CloudMD Software & Services subsidiary) (iMD) – a software company focused on health education – to provide credible health rehabilitation and wellness educational resources, to their customers across North America.

“We are very excited to provide our industry leading 3D animated and live video’s of over 50 medical conditions to facilitate patient understanding and rehabilitation to be included on the iMD platform, giving therapists and their patients credible information about their condition and recovery journey,” said Dr. Travis McDonough, Kinduct’s Founder and President. “We’re thrilled that therapists and patients will now have greater access to our video content to educate them on their condition and potentially how they can actively participate in their rehabilitation as they travel along the road to recovery.”

“The internet is used over 1 Billion times per day to search for health information, with very little accuracy, and there is no way to understand what is trusted / correct information, causing a great deal of misunderstanding,” said Kevin Delano, CEO & President of iMD, citing the need for accurate, reliable health information, particularly given the shift towards digital health tools incited by the pandemic. “We are excited to collaborate with Kinduct to provide our Providers and their Patients with credible, high quality rehabilitation and wellness information in a time when it is crucial to be properly informed."

Through iMD’s resources, full of user-friendly and visually appealing information, customers will access to vetted resources they can turn to for questions around their health concerns and the proper rehabilitation techniques (such as stretches, exercises, dietary, etc.). They will be then able to make more informed and responsible decisions, which is at the heart of a recovery-oriented, patient-centred approach.

About Kinduct Technologies
Kinduct’s Human Performance Platform supports athletic, medical, and tactical organizations around the world. Our clients include professional and national sporting organizations, health authorities and associations, and military and special forces groups. Kinduct’s cloud-based solution consolidates human performance and injury data to improve workflow for thousands of coaches, doctors, and trainers, while helping optimize the health and performance of athletes, patients, and tactical personnel. Kinduct is also integrated with many world-leading wearables, assessment and data collection technologies, turning rich data into powerful insights. To learn more visit:
https://www.kinduct.com/
For more information, contact Hayden Landry, Vice President
[e-mail]

About iMD Health Global
iMD Health Global is a Toronto-based eHealth software development company, focused on innovating healthcare education. Since 2010, iMD has grown into Canada’s largest digital patient engagement platform. Centred “At The Point of Care”®, healthcare professionals use iMD’s cloud-based platform (in clinic or virtual consults) to engage with their patients at a deeper level and optimize knowledge transfer surrounding a patient’s condition and treatment plan. This is done through the seamless integration of over 80,000 images, booklets, and video resources, (covering 2,100 medical topics) into an award-winning user interface that makes patient education both efficient and effective. At the end of a patient’s consult, a summary of all the discussed information can be emailed to the patient to review and continue their learning journey at home, improving their health literacy and adherence to their treatment plan. The iMD platform is utilized by over 10,000 clinicians (doctor’s, nurses, therapists, and pharmacists) in clinics, hospitals, pharmacies, infusion clinics, and in homecare settings. For more information please visit:
https://www.imdhealth.com/
and
https://app.imdhealth.com
iMD Health is a subsidiary of CloudMD Software & Services (TSXV: DOC)
For more information, contact Jared Sonnenberg, Vice President
[e-mail]

About CloudMD Software & Services
CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) is a telehealth company revolutionizing the delivery of healthcare to patients. CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.
http://www.cloudmd.ca/

For more information, contact Julia Becker, VP Investor Relations
[e-mail]

[StockpickerCAPC]

The top five Canadian equity analysts of 2020 – and their most profitable picks.

source
https://www.theglobeandmail.com/investing/investment-ideas/article-the-5-top-performing-canadian-equity-analysts-and-their-stock-picks-2/

020 was a wild ride for the stock markets.
Against the backdrop of a global pandemic, the markets rallied to new highs, with the TSX rounding out the year at 17,433.40.

At the same time, TipRanks, a financial technology company, tracked the performance of financial analysts who published recommendations throughout 2020, including ratings for the Canadian stock market....



Doug Taylor, Canaccord Genuity
Claiming the second spot on TipRanks’ ranking is Canaccord Genuity analyst Doug Taylor.

After graduating from Wilfrid Laurier University, Mr. Taylor kicked off his career as an Equity Research Associate at Thomas Weisel Partners, and later joined the team at TD as an Equity Research Analyst. Then, in 2015, he came on as Managing Director and Equity Research Analyst at Canaccord Genuity, covering the healthcare IT sector for the firm.

Over the past year, Mr. Taylor’s recommendations, on average, notched returns of 31.5 per cent. Additionally, his success rate for 2020 comes in at 77 per cent.

Out of all his picks during the course of the year, his “buy” rating on CloudMD Software & Services Inc. (DOC-X), a healthcare services provider that operates through brick-and-mortar clinics and telemedicine as well as pharmacies, was the most profitable. From June 16 through Oct. 16, shares soared 337.1 per cent.

Commenting on the company’s mixed Q3 results, Mr. Taylor noted, “These results reflect only a portion of the asset base the company has assembled through recent M&A activity,” with many acquisitions being finalized after the quarter wrapped up.

Since the beginning of June, CloudMD has announced 10 acquisitions, with the total consideration landing at roughly $57-million, including all cash, shares and potential earnouts. What’s more, Mr. Taylor points out that it has $60-million in cash that it could put towards additional M&A, which could fuel upside to his estimates.

“DOC trades at 9.2 times 2021 EV/Sales but we note that this valuation could be lowered should the company continue to deploy capital on accretive M&A,” Mr. Taylor added.

All of the above prompted Mr. Taylor to maintain a “buy” rating as well as a $3.25 price target on the stock.

[StockpickerCAPC]

See the video to the News of today on Twitter.

at:
https://twitter.com/CloudMD_SS/status/1354807616103346181

Today is #BellLetsTalk and now more than ever #mentalhealth is extremely important. We are dedicated to supporting mental health & wellness and reducing the stigma surrounding these issues.

Lets stay connected and support one another!

[StockpickerCAPC]

A RESEARCH AND FOLLOW UP POST - By StockpickerCAPC

CDC Report Reveals “Considerably Elevated” Mental Health Toll from COVID-19 Stresses.

source
https://jamanetwork.com/channels/health-forum/fullarticle/2770050

More than 2 in 5 US residents report struggling with mental or behavioral health issues associated with the coronavirus disease 2019 (COVID-19) pandemic, including anxiety, depression, increased substance use, and suicidal thoughts, according to new findings from the Centers for Disease Control and Prevention.
Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm

“Markedly elevated prevalences of reported adverse mental and behavioral health conditions associated with the COVID-19 pandemic highlight the broad impact of the pandemic and the need to prevent and treat these conditions,” the report noted.

The report, published in the August 14 issue of the Morbidity and Mortality Weekly Report, also notes that certain groups are disproportionately affected by COVID-19–related stresses, including younger adults, Black and Hispanic individuals, essential workers, unpaid caregivers for adults, and those receiving treatment for preexisting psychiatric conditions.

Two earlier? studies
Early Release of Selected Mental Health Estimates Based on Data from the January–June 2
https://www.cdc.gov/nchs/data/nhis/earlyrelease/ERmentalhealth-508.pdf

by CDC researchers had found a substantial increase in anxiety disorder and depressive disorder symptoms in the United States during April through June compared with the same time frame in 2019. To further assess mental health, substance use, and suicidal ideation during the coronavirus pandemic, researchers from the CDC and institutions in Boston, Massachusetts, and Melbourne, Australia, conducted representative panel surveys among US adults during late June.

Of 9896 eligible US adults 18 years or older invited to participate in the research, 5412 (approximately 55%) completed the web-based surveys during June 24 to 30. Overall, nearly 41% reported experiencing at least 1 adverse mental or behavioral health condition.

Nearly 31% reported symptoms of an anxiety or depressive disorder, 26% reported a trauma- or stressor-related disorder associated with the pandemic, and 13% said they had started or increased substance use “to cope with stress or emotions related to COVID-19.” Nearly 11% of respondents said they had seriously considered suicide in the preceding 30 days, more than twice the rate reported in a 2018 survey. - 82 Pages
Key Substance Use and Mental Health Indicators in the United States:
Results from the 2018 National Survey on Drug Use and Health
https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf

These symptoms and behaviors disproportionately affect certain groups. More than half of respondents agesd18 to 24 years (74.9%) or 25 to 44 years (51.9%) reported having at least 1 mental or behavioral health symptom, as did the majority of respondents who were Hispanic (52.1%), held less than a high school diploma (66.2%), were essential workers (54.0%) or unpaid caregivers for adults (66.6%), or were already receiving treatment for previously diagnosed anxiety (72.7%), depression (68.8%), or posttraumatic stress disorder (88.0%) at the time of the survey.

Certain groups also show a disproportionately high risk for suicide ideation. Those who had seriously considered suicide in the past 30 days included respondents aged 18 to 24 years (25.5%), Hispanic (18.6%) and Black (15.1%) respondents, individuals with less than a high school diploma (30.0%), essential workers (21.7%), and unpaid caregivers for adults (30.7%).

These same groups were also disproportionately more likely to start or increase substance use to cope with pandemic-related stress or emotions, including respondents aged 18 to 24 years (24.7%), Hispanic (21.9%) and Black respondents (18.4%), essential workers (24.7%), and unpaid caregivers for adults (32.9%).

The authors’ analysis of responses of 1497 individuals who had completed the survey, along with related surveys during April 2 to 8 and May 5 to 12, revealed a particularly high burden of distress among unpaid caregivers for adults. Compared with others, they were significantly more likely in June than in May to start or increase substance use and to report seriously considering suicide.

The report noted that many unpaid caregivers of adults are currently providing “critical aid to persons at increased risk for severe illness from COVID-19” and that approximately 39% of these caregivers (compared with 27% of other survey respondents) shared a household with children. “Caregiver workload, especially in multigenerational caregivers, should be considered for future assessment of mental health, given the findings of this report and hardships potentially faced by caregivers,” the authors added.

To address mental health disparities and prepare support systems to lessen adverse mental health consequences as the pandemic evolves, the researchers urge provision of social support, comprehensive treatment options, and harm reduction services to address substance use related to COVID-19 stresses. They also note that expanded use of telehealth to deliver treatment for mental health conditions might help reduce COVID-19–related mental health consequences.

Community-level efforts to promote health services and communicate culturally and linguistically tailored messages about practices to improve emotional well-being also “should prioritize young adults, racial/ethnic minorities, essential workers, and unpaid adult caregivers,” they said.

According to the Commonwealth Fund’s
2020 Commonwealth International Health Survey
Do Americans Face Greater Mental Health and Economic Consequences from COVID-19? Comparing the U.S. with Other High-Income Countries
https://www.commonwealthfund.org/publications/issue-briefs/2020/aug/americans-mental-health-and-economic-consequences-COVID19

of more than 8000 adults from March 30 to May 25, 2020, US adults were shouldering
a heavier mental health burden
COVID-19 Mental, Economic Stresses Worse for US Public than for Those in Other Wealthy Countries.
https://jamanetwork.com/channels/health-forum/fullarticle/2769483?resultClick=1

from COVID-19–related stresses, such as social isolation and greater economic challenges, compared with their counterparts in other high-income countries.

[StockpickerCAPC]

CloudMD Launches Mental Health Technology Platform and Support Services in the United States.

source
http://www.digitaljournal.com/pr/4968106

VANCOUVER, British Columbia, Feb. 09, 2021

- Proprietary technology platform immediately available for corporations and providers across all 50 states in the U.S. to better manage the health and wellbeing of their employees

- Expands established U.S. footprint to include physical care and mental health support

- More than 2 in 5 residents in the U.S. report struggling with mental or behavioral health issues associated with COVID-19 pandemic, including anxiety, depression, increased substance use, and suicidal thoughts

- Integral step in CloudMD’s North American expansion strategy to integrate solutions to provide one, centralized healthcare platform to provide seamless, whole-person care to patients

CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a healthcare technology company revolutionizing the delivery of care to patients, is excited to announce that it has expanded its mental health services into the United States. Snapclarity Inc. (“Snapclarity”), CloudMD’s mental health solution is now available for providers and corporations (B2B) in the United States through its proprietary technology app, providing individuals with direct access to clinical assessments that: support risk and diagnosis, provide an immediate connection to care that allows individuals to self-manage, create responsive coping mechanisms and control symptoms through the delivery of personalized therapeutic support.

There is an immediate demand for mental health services in North America. According to the Centers for Disease Control and Prevention, more than 2 in 5 residents in the U.S. report struggling with mental or behavioral health issues associated with COVID-19 pandemic, including anxiety, depression, increased substance use, and suicidal thoughts.

Combined with iMD Global Health which is already available in the U.S., CloudMD’s mental health services provide support around various mental health issues, personalized care pathways and valuable educational resources for corporations and insurers to provide better access to care and improved, holistic treatment options to manage the health and wellbeing of their employees and family members. The platform is currently utilized by employers, individuals, therapists and insurers and offers a continuity of care program that effectively blends the supported intervention with technology, artificial intelligence and human touch. This is accomplished through a suite of proprietary digital tools that are designed by clinicians and grounded in evidence-based practices that are proven to positively impact outcomes.

CloudMD’s Employee Assistance Program provider, HumanaCare Inc. (“HumanaCare”), also has an existing client base in the U.S. and by integrating Snapclarity’s software into the platform, HumanaCare will improve the current client offering, and will continue to expand its enterprise footprint with this integrated, whole-person solution.

CloudMD already has a significant footprint in the U.S. including Benchmark Systems, which offers revenue cycle management/billing solutions, practice management and electronic medical records software, and services 200 clients, 800 physicians, across 5.5 million patient charts in 35 states. Further, the Company acquired IDYA4, as its technology enabler for future digital transformation and interoperability in the healthcare space. Currently IDYA4’s data platform is used at federal and state levels in partnership with the Department of Justice, Homeland Security and Health and Human Services to name a few. CloudMD remains focused on its U.S. expansion and rolling out its mental health services to its current footprint as well as new enterprise clients is an important next step in that strategy.

CloudMD has grown its network of medical professionals which now includes: 7,000 psychiatrists, over 4,500 therapists and counsellors, over 4,000 psychologists, over 22,000 family physicians, 34,000 medical specialists, over 1,500 allied health professionals and a dedicated research team across North America. This extensive network is the foundation for CloudMD to scale and grow its healthcare platform quickly and efficiently.

Amit Mathur, President of CloudMD commented, “We have an aggressive multi-pronged North American expansion plan that includes both physical and mental health services. We recognize the significant opportunity and need for mental health support in the United States and now we can support corporations and providers to better manage the mental health needs of the workforce. With our local expertise and infrastructure in place, we expect to see significant growth in the U.S. as we continue with the integration of our solutions.”

About Snapclarity
Snapclarity is a pioneer, on-demand, digital platform that provides an assessment for mental health disorders which includes a personalized care plan, access to online resources, a clinical health care team and the ability to match to the right therapists. To learn more about Snapclarity visit:
www.snapclarity.com
and to download the individual app please visit the Apple Store and/or the Google Play Store. For more corporations and insurers needing more information on the suite of services please contact:
[e-mail].

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America. For more information on CloudMD visit
www.cloudmd.ca.

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[GorillaDaddy]

Getting ready for LIFT OFF

[GorillaDaddy]

Looking like we’re getting ready for more sideways then up!!!

[StockpickerCAPC]

CloudMD to Drive North American Clinic Expansion with Seasoned Leadership.

source
http://www.digitaljournal.com/pr/4955438

VANCOUVER, British Columbia, Jan. 28, 2021

CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telehealth company seeking to revolutionize the delivery of healthcare to its patients, is excited to announce that it has appointed a new VP, Clinic Operations to integrate and lead its current network of clinics and continue driving expansion across every province of Canada and strategically in the United States.

Kristine Heckman is joining CloudMD as VP Clinic Operations and is the latest addition to the Company’s management team. Kristine brings over 20 years of industry experience, most recently as VP, Clinic Operations with Lifemark Health, a national rehabilitation company with over 200 locations across Canada. In her role with Lifemark Health, she was responsible for managing and leading the operations and financial performance of their multidisciplinary clinic network across British Columbia. Kristine was also responsible for supporting growth and expansion through M&A activities and integrating new clinics into Lifemark Health’s existing network. She was accountable for establishing and adhering to best practice quality of care standards and customer satisfaction as well as executing new corporate initiatives to ensure execution of standard operating procedures.

CloudMD’s mission is to deliver patient centric, whole-person healthcare and the Company is committed to providing longitudinal support to its patients. CloudMD’s current clinic network includes 14 clinics, 95 practitioners servicing over 500,000 patients. The Company is focused on expanding a hybrid (in-person and virtual) clinic network in every province across Canada and strategically in the United States to enable patients to consult with a doctor, specialist or therapist when and where they need it. Kristine will be responsible for leading the integration, operations and financial performance of CloudMD’s strategic growth of its business operations and will assist management and corporate development leadership identify clinic partners that align with CloudMD’s mission and vision for patient care and growth. She will also take the lead and drive the integration of best practices and quality of care within the network.

Essam Hamza, CEO of CloudMD commented, “We are delighted to welcome Kristine to our leadership team as VP, Clinic Operations. With over 20 years’ experience with companies like Lifemark and Centric Health, she is a well-regarded industry leader and will be a valuable part of our operations team as we continue to focus on our clinic expansion strategy. CloudMD has achieved significant growth in a very short amount of time, and as we continue to establish the foundation to expand the business, Kristine will be a key leadership pillar for our clinical division.”

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[GorillaDaddy]

Ignore — got distracted — thanks

[GorillaDaddy]

What is this?

[StockpickerCAPC]

https://www.rxinfinity.ca/

Caring is our specialty. - We think and act differently.

With a deep commitment to patient centric care, our nurses, pharmacists and patient care coordinators elevate and improve the patient journey and the healthcare provider experience.

Let’s talk

Head Office
Unit 29-5155 Spectrum Way
Mississauga, Ontario L4W 5A1

Questions?
[e-mail]

Contact?
P: 1-844-621-CARE (2273)
F: 1-844-631-CARE (2273)

[StockpickerCAPC]

CloudMD to Acquire Rxi Group of Companies, an Established One-Stop Patient Support Logistics Company and Leading Customer Relationship Management Technology Provider.

source
https://finance.yahoo.com/news/cloudmd-acquire-rxi-group-companies-123000751.html

CloudMD Software & Services Inc.- Tue, January 26, 2021, 1:30 PM

Adds $16.6 million in revenue and increases CloudMD’s current annualized run-rate to over $60 million.
Rxi’s pharmaceutical logistic services include drug distribution, patient navigation assistance, a preferred network of over 500 pharmacies and real-time universal disease management software.

Rxi oversees several national and provincial patient support programs and provides administrative and drug benefit management services to a large third-party benefits provider.

Proprietary Customer Relationship Management (CRM) technology that is sector agnostic and that can be white-labelled.

CloudMD’s acquisition of Rxi supports two key objectives: 1) Enhances specialty health services to patients, providers, payers and manufacturers and 2) expands both the suite of offering for enterprise clients and the potential to cross sell existing services to new enterprise clients.

VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telehealth company revolutionizing the delivery of healthcare to patients, is excited to announce that it has signed a binding term sheet (“Term Sheet”) to acquire Rx Infinity Inc., Rxi Pharmacy Inc., and Rxi Health Solutions Inc., (collectively “Rxi”), enhancing its specialty health services to patients, providers, payers and manufacturers in Canada.

Rxi’s pharmaceutical logistic services include drug distribution, patient navigation assistance, a preferred pharmacy network of over 500 pharmacies and real time universal disease management software. Historically, patient support programs have been geared towards improving product access and outcomes rather than holistic disease management and linkage to care and clinical interventions that ensure proper medication adherence and better overall health outcomes. As a proven solution to the currently siloed healthcare system, Rxi’s combined offerings provide a one-stop solution and centralized platform that breaks down treatment barriers by offering a team-based, real time, longitudinal approach to patient care and disease management. Rxi oversees several national and provincial patient support programs, specializing in Oncology, Infectious Diseases and Inflammatory Bowel Disease (IBD). The company also provides administrative and drug benefit management services to a large third-party benefits provider, servicing more than 300,000 patients across Canada. Rxi is also licensed as a National Wholesaler (GMP certified), approved by Health Canada.

(My StockpickerCAPC comment: "YEAH")

Speciality drugs are defined as high-cost prescription medications used to treat complex, chronic conditions. In Canada, less than 1% of claimants accounted for 30% of total eligible costs in 2019 and specialty drugs are forecast to account for almost 46% of the average monthly certificate cost by 2025(1). Often times these drugs are very costly, difficult to access and challenging to navigate for patients, physicians, and pharmaceutical companies, leading to suboptimal outcomes across all therapeutic areas. Rxi’s platform focuses on user experience and personalizes patients' complete healthcare journeys.

The acquisition of Rxi will be synergistic across CloudMD’s platform of healthcare technology solutions and will be integrated with its electronic medical records (“EMR”) software, educational resources, healthcare navigation and enterprise health services. The addition of Rxi will expand CloudMD’s pharmacy offering and distribution and fulfillment channel across Canada. CloudMD will have access to Rxi’s network of 500 independent pharmacies to provide better, more localized, access to care.

Rxi was founded by CEO, Christian Marcoux, who has over 20 years’ experience within the specialty drug industry and has effectively launched and managed dozens of national patient support programs across Canada in various therapeutic areas. Previous to starting Rxi, Christian spent almost 13 years at Shoppers Drug Mart as part of the senior management team leading the Speciality Health Network.

Rxi's annualized revenue for calendar year 2020 is approximately $16.6 million with earnings before interest, taxes, depreciation and amortization (“EBITDA”) of approximately $600,000(2). Rxi generates revenue through (1) wholesale and dispensary services, (2) licensing for its proprietary technology and (3) pharmacy partnerships. Upon closing, the acquisition of Rxi will be immediately accretive to CloudMD with synergies the company believes will drive further revenue and increased EBITDA margins through cross-selling and integration across its portfolio of healthcare technology solutions.

Dr. Essam Hamza, CEO of CloudMD commented, “The acquisition of Rxi is transformational for CloudMD and aligns with our vision and focus of providing holistic, patient focused care. It will be immediately accretive to our top line while adding new revenue streams and driving value and growth across many verticals of our business. Their revolutionary disease management software can be integrated into many of our healthtech solutions including our EMR platforms, IMD’s patient education platform, enterprise health services and pharmacy and clinic networks. It also provides a comprehensive platform to better care for complex and chronic care patients and gives us the ability to distribute and fulfill prescription drugs nationally. We welcome Christian and his team to the CloudMD family and look forward to working with them to continue unlocking value.”

Christian Marcoux, Chief Executive Officer of Rxi commented, “CloudMD’s acquisition of Rxi represents a transformational shift in the evolution and delivery of highly specialized patient support programs. Rxi will be able to optimize and cross-sell into CloudMD’s current client network by offering manufacturers and payers more comprehensive solutions and real-time visibility into the patient journey, something that has been lacking in our industry for well over a decade. CloudMD’s telemedicine expertise combined with Rxi’s universal disease management experience and customizable software will significantly improve communication and transparency across multi-disciplinary stakeholder groups; thus, enabling quicker access to treatments and improved clinical treatment outcomes.”

Terms of Acquisition
In consideration for the purchase of 100% of the outstanding securities of Rxi, CloudMD has agreed to pay shareholders of Rxi aggregate consideration of $9.5 million payable as follows: (i) $2.5 million in cash, subject to a working capital adjustment; (ii) $4 million in common shares of the Company; and (iii) a performance-based earnout of $3 million, which is payable in common shares of the Company in equal annual issuances over a period of two years. All common shares issued pursuant to the acquisition will be issued at a deemed price of $2.39 per common share and are priced by calculating the 10-day volume-weighted average trading price of the Company's common shares for the 10 trading days prior to the execution of the binding term sheet. The common shares will be subject to certain contractual restrictions on trading for a period of 20 months from the date of issuance.

The acquisition is subject to customary closing conditions, including the execution of a definitive acquisition agreement and receipt of TSX Venture Exchange approval.

(1) https://plus.telushealth.co/blogs/health-benefits/wp-content/uploads/AST2986-Drug-Trends-Report-July-2020-EN-V6.pdf

(2) Annualized revenue figures are calculated based on annualizing the available results for the 11-month period ending Nov. 30, 2020.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America. For more information visit: investors.cloudmd.ca

About Rxi
Rxi is a Canadian based specialty drug wholesaler, pharmacy and technology/patient support program administrator. The company develops customized programs for a variety of clients that offer end-to-end solutions to optimize holistic disease management and clinical treatment outcomes for patients requiring complex and expensive pharmaceutical treatments. For more information visit: www.rxinfinity.ca


ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[StockpickerCAPC]

Outlook

source
https://www.streetinsider.com/Globe+Newswire/CloudMD+Reports+Record+Revenue+of+%243.4+Million+in+Q3+2020/17662795.html

The Company is focused on revolutionizing the healthcare industry by leveraging technology to digitalize its delivery to provide both better access to care which leads to better health outcomes. CloudMD has a strong balance sheet with approximately $60 million in cash, which will allow it to continue deploying capital on a robust pipeline of accretive, synergistic acquisitions. Subsequent to the quarter, the Company completed five strategic acquisitions which enhances its portfolio of SaaS model digital services and clinic services offering. The Company also announced another four acquisitions, primarily focused on its newly created Enterprise Health Solutions Division, which are expected to close by December 31, 2020.

CloudMD’s organic growth will be largely driven by its network of hybrid clinics, pharmacy partnerships, SaaS solutions and enterprise partnerships. Through its recent acquisitions, there are opportunities for cross-functional synergies and cross selling that will drive further organic growth.

With our Q3 2020 financial performance, combined with organic growth, and completed and announced acquisitions, CloudMD is on track to achieve (i) annualized revenue run rate exceeding $35 million, (ii) gross margin exceeding 50%, and (iii) improved Adjusted EBITDA performance.

CloudMD will continue to focus on delivering meaningful shareholder value by executing on its growth strategy through accretive acquisitions, strategic capital allocation and continuing to achieve organic growth across all divisions.

[StockpickerCAPC]

CloudMD Closes Acquisition of Canadian Medical Directory, the Largest Medical Directory in Canada.

source
https://finance.yahoo.com/news/cloudmd-closes-acquisition-canadian-medical-123000970.html

CloudMD Software & Services Inc. - Fri, January 22, 2021, 1:30 PM

Largest directory of trusted, highly-segmented information on 91,000 practicing physicians and 10,000 residents and nurse practitioners.

VANCOUVER, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telehealth company revolutionizing the delivery of healthcare to patients, is pleased to announce that it has closed the previously announced acquisition of Canadian Medical Directory (“CMD”), Canada’s largest, most trusted, directory of medical professionals including 91,000 practicing physicians and 10,000 residents and nurse practitioners across the country. The robust, multi-layered database is genuinely unique as no other direct competitor has a SaaS platform that collects and vends the data in such a highly segmented, up-to-date way.

CMD has been trusted as the gold standard for up-to-date information on all medical professionals across Canada in a standard national format. CMD is Canada’s leading source for profile and contact information on practicing physicians, specialists and nurse practitioners, across the country. It’s a key reference tool used by clinics, hospitals, medical placement firms, pharmaceutical companies, and manufacturers and distributors of medical equipment and supplies.

CloudMD will be able to integrate the CMD database into its Juno EMR, billing, virtual care and telehealth platforms, as well as iMD Health’s leading educational resource databank. CloudMD will leverage the CMD brand, customer network and data, to power up and accelerate doctor acquisition and adoption. In addition, CloudMD will use its suite of products and resources to continue building and growing CMD’s robust database.

CMD generated approximately $450,000 in high margin, 100% SaaS based revenues with earnings before interest, taxes, depreciation and amortization (EBITDA) margins exceeding 65%, resulting in an EBITDA of approximately $293,000 over the 12 month period ending September 30, 2020. The Company believes that there is significant opportunity to further optimize the revenue through integration and optimization.

Terms of Agreement
In consideration for the purchase of 100% of the assets and business of CMD, CloudMD has agreed to pay aggregate consideration of approximately $2.037 million payable as follows: (i) $250,000 in cash; (ii) approximately $1.42 million in shares of the Company; and (iii) a performance-based earnout of $368,000, which is payable in shares of the Company in annual issuances over a period of two years. All shares issued pursuant to the acquisition are issued at a deemed price of $2.47 per share and are priced by calculating the 10-day volume-weighted average trading price of the Company's shares for the 10 trading days prior to the execution of the binding term sheet (Press release dated October 21, 2020). The shares will be subject to certain contractual restrictions on trading for a period of 16 months from the date of issuance.

About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD"
Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]

[GorillaDaddy]

Sweet. I’m loaded.

[happyglass]

I do not think so, it is taking a breather after a huge run. They are setting up a network for the future of digital medicine.

[GorillaDaddy]

This thing dead or what?!

[happyglass]

Dow Jones
12/17/2020 07:31 AM ET
* Press Release: CloudMD to Acquire IDYA4, a North American Leader in Healthcare Data Integration and Cybersecurity
CloudMD to Acquire IDYA4, a North American Leader in Healthcare Data Integration and Cybersecurity
-- Innovative, health data integration and security technology solution
leveraging various information sharing standards supported by the U.S.
Department of Justice, the U.S. Department of Homeland Security, U.S
Health and Human Services and currently in use by the various Government
agencies at the Federal, State and Local level.

-- Will expedite CloudMD's integration of healthcare solutions providing one,
digitally connected, patient focused platform.

-- Solution will be CloudMD's technology backbone for continued growth
through implementing new technology applications, health-tech solutions
and wearable devices.

-- Provides immediate pathways for North American expansion and
cross-selling opportunities to already established client network.

-- Best in class cybersecurity features support U.S. and international
security standards.

-- Immediately synergistic and accretive, expecting approximately US$ 4.1M
revenue in calendar year 2020 with EBITDA margins of 36% with a strong
revenue pipeline and growth opportunities.
VANCOUVER, British Columbia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the "Company" or "CloudMD"), a healthcare technology company revolutionizing the delivery of care, is excited to announce that it has signed a binding term sheet (the "Agreement") to acquire IDYA4, a leading data integration and cybersecurity company based in the United States.
Focused on the health and wellness sector, IDYA4 has built a proprietary technology platform that provides improvements in data access, management, security and integration, as well as proactively providing protection against today's ever-changing cyber threats. Built on over 20 years of experience, the IDYA4 team has been at the forefront of the development of information sharing and interoperability solutions across all 50 states for clients including, U.S. Department of Justice, the U.S. Department of Homeland Security, U.S Health and Human Services, and National Intelligence. Global legislations are evolving to ensure patients have access to their own healthcare data and are empowering them to take control of their healthcare journeys. IDYA4's health data platform already leverages critical national and international technology standards and allows providers and patients access to sensitive and private health data in an efficient and intuitive manner with adherence to privacy and security regulations.
The IDYA4 platform is designed to allow various health technology solutions like Electronic Medical Records (EMR), Apps, telehealth solutions and medical devices to connect and share data with all the relevant privacy and data security rules applied that can vary state to state or program to program. The IDYA4 software and team will also immediately help accelerate CloudMD's integration of its healthcare technology solutions to provide one, digitally connected platform to enable team-based, continuity of care and an ecosystem of healthcare providers focused on the overall health and wellness of the patient. The integrated technology will also be valuable as CloudMD continues to emphasize patient engagement through connected technology, healthcare portals, telehealth applications, and wearable devices.
In addition to accelerated integration, CloudMD will be able to leverage IDYA4's already existing relationships and cross-sell its suite of healthcare solutions and enterprise healthcare platform to these clients. This includes offering solutions such as Livecare, Benchmark, Snapclarity and iMD Global Health to IDYA4's existing and prospective clients to provide an enhanced health and wellness offering.
Using their standard-based interoperable platform, IDYA4 has developed several applications which have been commercialised and continues to develop and add to their portfolio of solutions to address the evolving healthcare landscape and the unmet demand for innovative and secure healthcare solutions. The recently launched Health and Wellness Platform will be deployed to assist First Responders initially and will be rolled out to Public Health, Professional Sports and other communities. This program will address the issues of Behavioural Health including Mental Health and Substance Use Disorder heightened by the COVID-19 pandemic across North America, and will be the core component of CloudMD's enterprise health solutions.
CloudMD is committed to the privacy and security of patient data, and this integrated health data platform is Health Insurance Portability and Accountability Act (HIPAA) compliant and is enabled for continuous monitoring to ensure the protection and privacy of sensitive data. The platform has been architected to support U.S. and International security standards like the National Institute of Standards and Technology (NIST) Cybersecurity Framework to address internal and external cyber threats.
Amit Mathur, President of CloudMD commented, "Earlier this year we entered into a vendor resale agreement with IDYA4, but after working closely together for a number of months, it's evident that the synergies between both companies will be instrumental in accelerating the integration of CloudMD's solutions, continuing the growth and expansion across North America and lastly, ensuring state of the art intelligence and cybersecurity across the platform." He continued, "The future of healthcare delivery is patient-focused, team-based and digitally connected. This is an exciting inflection point for our Company, as the acquisition of IDYA4 provides CloudMD with a backbone of innovative, proprietary data integration and security technology that will position us as leaders in the healthcare technology sector."
"Healthcare data integration and security is a complex and critical problem that must be addressed on a global basis. IDYA4 has prioritized this issue to help government agencies and private health care entities to establish secure integration using a globally recognized standards-based integrated health data platform. Changes are occurring rapidly in current global healthcare legislation to empower patients and ensure their ability to access personal healthcare records and share what is needed with confidence and assurance of its safety. Our team's capabilities and depth of knowledge on standards for sharing information, combined with the expertise offered by CloudMD, will provide a holistic, patient-centric approach to care, based on one single and connected platform, transforming the way healthcare is being delivered. We look forward to working jointly with CloudMD, and through our combined knowledge, expand and grow the capabilities for the critical healthcare environment," commented, Ashwini Jarral Co-Founder, Chief Operating Officer of IDYA4.
IDYA4's current annualized revenue run rate, based on the 9-month period ending September 31, 2020, is approximately US$ 4.1-million with EBITDA (earnings before interest, taxes, depreciation and amortization) margins of 36%. Upon closing, the acquisition of IDYA4 will be immediately accretive to CloudMD with synergies the Company believes will drive further revenue and increased EBITDA margin through cost savings achieved through the scaling of operations and by tapping into CloudMD's current health technology solutions that will be added to IDYA4's current product portfolio. From IDYA4's currently commercialised products, the Company expects to achieve an annual Revenue growth rate greater than 45%, calculated based on expected revenue from currently committed and/or high probability contracts forecasted to generate annual gross revenue greater than US$ 6M and US$ 8.5M in calendar years 2021 and 2022, respectively. A total of 30% of the total consideration for the acquisition amounting to US$ 4.44 million is based on two performance based earnouts, 15% each, that are contingent on meeting these forecasted revenue targets.
Terms of agreement
In consideration for the purchase of 100% of the issued and outstanding IDYA4 Securities, CloudMD has agreed to pay aggregate consideration of US$14.8 million payable as follows: (i) US$ 3.7 million in cash, subject to a working capital adjustment; (ii) US$ 6.66 million in common shares of the Company; and (iii) a performance based earnout of US$ 4.44 million, of which US$ 0.44 million is payable in cash and US$4 million is payable in common shares of the company in equal annual issuances over a period of two years. All common shares issued pursuant to the acquisition are issued at a deemed price of $2.16 per share and are priced by calculating the 10-day volume-weighted average trading price of the Company's shares for the 10 trading days prior to the execution of the binding term sheet. The shares will be subject to certain contractual restrictions on trading for a period of 30 months from the date of issuance.
The acquisition is subject to customary closing conditions, including the execution of a definitive acquisition agreement and receipt of TSX Venture Exchange approval.
About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America. For more information visit: www.cloudmd.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
"Dr. Essam Hamza, MD"
Chief Executive Officer
FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
(MORE TO FOLLOW) Dow Jones Newswires
December 17, 2020 07:31 ET (12:31 GMT)
Press Release: CloudMD to Acquire IDYA4, a North -2-
VP, Investor Relations
[e-mail]
Forward Looking Statements
This news release contains forward-looking stateme

[GorillaDaddy]

Looking at acquiring some shares here. Looks like they're staircasing down.

Anyone feeling this coming back life? The cash flow is great. I mean if they can keep their operating costs at what they are 3x or improve they will have plenty of run time to get profitable I would hope. lol

1.60 looks like a key level here. maybe we downzoooooooo!

[hiroller12x]

encouraging day when you consider it could have cut twice as deep...
missed the chance this week to "show us (and the street) the money".

IMO 2Qs to have a glimpse of the $$ future here if covid doesn't overstay it's welcome and 400 different companies tout they've come up with " the vaccine" one right after the others as they chase the brass ring.

red days ahead imo...but significant credible news may poke a finger in the dam for the near term. Hope the market holds together....

[kickask]

Looks like another deal closed today as well. Two in two days.

CloudMD Closes Acquisition of Re:Function, a Profitable Rehabilitation Clinic Network

$5.8 million in revenue and over 19% EBITDA

VANCOUVER, British Columbia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the "Company" or "CloudMD"), a telehealth company revolutionizing the delivery of healthcare to patients, is pleased to announce that it has closed the previously announced acquisition of Re:Function Health Group Inc. ("Re:Function"), a leading rehabilitation clinic network, with 8 clinics and 37 specialists and allied health professionals.

Dr. Essam Hamza, CEO of CloudMD commented, "We are excited to close the acquisition of Re:Function and have already started working with the entire team. Through strategic M&A, we have acquired a number of already successful standalone healthcare solutions that combined, will create one transformative platform that emphasizes whole-person care. The integration of these solutions is already very much underway and already showing early beneficial results. I am extremely proud of our team for their diligence and focus in building the solid foundation which has enabled CloudMD to be a leader in the space."

Re:Function is a state-of-the-art rehabilitation company built by like-minded health professionals offering superior patient focused care, with a longitudinal approach to healthcare delivery. Re:Function provides assessments for enterprise clients, insurers and corporations for long-term disability claims and return to work outcomes. CloudMD will integrate its telemedicine solutions throughout the clinics, layering on additional allied health and specialist functions to the platform. The practice is made up of four key rehabilitation pillars, Re:Build (physiotherapy), Re:Think (counselling), Re:View (medlegal consulting) and Re:Tool (vocational rehabilitation), and a team of specialists including: Occupational Therapists, Physiotherapists, Kinesiologists, Psychologists, Psychiatrists and Counsellors.

The acquisition will be immediately accretive to CloudMD as the Re:Function group of clinics generated approximately $5.8 million in revenues with earnings before interest, taxes, depreciation and amortization (EBITDA) margins exceeding 19% over the last fiscal year ending January, 2020.

Re:Function's principle Directors, Ralph Cheesman and Mike Smith, both Occupational Therapists, will be joining CloudMD to lead the continued expansion of allied health services across North America, and together will provide a multidisciplinary, team-based approach to treatment.

Terms of Agreement

In consideration for the purchase of 100% of the outstanding securities of Re:Function, CloudMD has agreed to pay shareholders aggregate consideration of C$8,000,000 payable as follows: (i) C$3,000,000 in cash, subject to a working capital adjustment; (ii) C$3,500,000 in shares of the Company; and (iii) a performance-based earnout of C$1,500,000, which is payable in shares of the Company in annual issuances over a period of three years. All shares issued pursuant to the acquisition are issued at a deemed price of C$0.88 per share and are priced by calculating the ten-day volume weighted average trading price of the Company's shares for the 10 trading days prior to the execution of the binding term sheet executed on August 21, 2020. The shares will be subject to certain contractual restrictions on trading for a period of thirty months from the date of issuance.

About Re:Function Health Group

Re:Function is a state-of-the-art rehabilitation company built by like-minded health professionals offering superior patient focused care, with a longitudinal approach to healthcare delivery. The practice is made up of four key rehabilitation pillars, Re:Build (physiotherapy), Re:Think (counselling), Re:View (medlegal consulting) and Re:Tool (vocational rehabilitation), and a team of specialists including: Occupational Therapists, Physiotherapists, Kinesiologists, Psychologists, Psychiatrists and Counsellors. For more information visit www.refunction.ca

About CloudMD Software & Services

CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS

"Dr. Essam Hamza, MD"

Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:

Julia Becker

VP, Investor Relations

[e-mail]

Forward Looking Statements

This news release contains forward-looking statements that are based on CloudMD's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business. Although CloudMD believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and CloudMD undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Non-GAAP and Non-IFRS Measures

This press release refers to "EBITDA" and "EBITDA margins" which are non-GAAP and non-IFRS financial measures that do not have a standardized meaning prescribed by GAAP or IFRS. The Company's presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These financial measures are intended to provide additional information to investors concerning the Company's and Re:Function's performance. EBITDA is defined as earnings before interest, taxes, depreciation and amortization and EBITDA margins is defined as EBITDA as a percent of total revenue. EBITDA and EBITDA margins are Non-IFRS measures the Company uses as an indicator of financial health and excludes several items which may be useful in the consideration of the financial condition of the Company and Re:Function, as applicable, including interest expense, income taxes, depreciation, and amortization.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

[happyglass]

Here is a new deal announced today, I imagine the price will drop on the news but I see it as accretive.

CloudMD Closes Acquisition of iMD Health Global Corp., a Revolutionary Patient Engagement Software Company
VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the "Company" or "CloudMD"), a telehealth company revolutionizing the delivery of healthcare to patients, is pleased to announce that it has closed the previously announced acquisition of iMD Health Global Corp. ("iMD"), a novel, award winning platform designed for healthcare professionals at every level of care to better engage, inform and educate patients about their conditions and treatment plans. The platform features trusted, peer-reviewed healthcare resources.
iMD is a trusted platform used by healthcare professionals (including doctors, nurses, pharmacists and allied health professionals), to provide factual, medical information that promotes positive patient behaviour in all health sectors. iMD's intuitive platform provides a robust digital library and consultative visual component which is available on any digital device. iMD's platform is populated with content licensing partnerships with Canada's most respected health associations, pharmaceutical companies in addition to being backed and partnered with Apotex Pharmaceuticals, one of Canada's largest pharmaceuticals companies with $2 billion in annual sales, which currently has an 18% equity stake in iMD.
The platform has access to over 7.5 million patients and is currently being used by over 10,000 healthcare professionals and other users including: 3,800 doctors, 2,000 pharmacies, 140 hospitals, and 150 specialty clinics. In addition, iMD has partnerships with over 30 global pharmaceuticals companies, 18 digital healthcare integration providers, Health Canada and over 60 healthcare associations in North America. iMD's robust medical library already has over 80,000 patient friendly images, brochures and videos covering 2,100 health conditions, which includes the medical Mayo Clinic library. The platform has a great return on investment (ROI) for healthcare practitioners as it increases efficiency, improves patient engagement, reduces costs and saves time.
Kevin Delano, CEO and Founder of iMD has plans to expand iMD across Canada, North America, Mexico and the Middle East. Kevin has been leading iMD for the last 10 years and has a strong entrepreneurial background, having created / co-founded a number of businesses in the sales and marketing disciplines. The iMD team will have access to CloudMD's resources and capital to expedite its expansion and continue growing the business. Kevin will be responsible for leading the continued global expansion of iMD.
Terms of Agreement
In consideration for the purchase of 100% of the outstanding securities of iMD, CloudMD has agreed to pay shareholders aggregate consideration of C$10,000,000 payable as follows: (i) C$1,500,000 in cash, subject to a working capital adjustment; (ii) C$4,500,000 in shares of the Company; and (iii) performance-based earnouts of C$4,000,000 which is payable in shares of the Company in annual issuances over a period of two years. All shares will be issued at a deemed price of C$1.61 per share and are priced by calculating the ten-day volume weighted average trading price of the Company's shares for the 10 trading days prior to the execution of the binding term sheet. The shares will be subject to certain contractual restrictions on trading for periods ranging from eight and twenty months from the date of issuance.
About iMD Health Global Corp.
iMD Health Global is a Toronto-based ehealth software development company, focused on innovating healthcare education. Since 2010, iMD has grown into Canada's largest digital patient engagement platform. Centered "At The Point of Care"(R), healthcare professionals use iMD's cloud-based platform (in clinic or virtual consults) to engage with their patients at a deeper level and optimize knowledge transfer surrounding a patient's condition and treatment plan.
This is done through the seamless integration of over 80,000 images, booklets, and video resources (covering 2,100 medical topics), into an award-winning user interface that makes patient education both efficient and effective. At the end of a patient's consultation, a summary of all the discussed information can be emailed to the patient to review and continue their learning journey at home, improving their health literacy and adherence to their treatment plan. The iMD platform is utilized by doctors, nurses and pharmacists in clinics, hospitals, pharmacies, infusion clinics and in-home care settings. Learn more at imdhealth.com.
About CloudMD Software & Services
CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.
ON BEHALF OF THE BOARD OF DIRECTORS
"Dr. Essam Hamza, MD"
Chief Executive Officer
FOR ADDITIONAL INFORMATION CONTACT:
Julia Becker
VP, Investor Relations
[e-mail]
Forward Looking Statements

[happyglass]

I think this one has great potential

[KISSINGER]

Go where? Where did it go? To the Toxic dump?

[happyglass]

Health technology provider CloudMD agrees to acquire HumanaCare for C$17.5M
Author Lovelyn Tagalag
Theme Healthcare & Pharmaceuticals
CloudMD Software & Services Inc. signed a binding term sheet to acquire HumanaCare Inc., a provider of mental and physical wellness services for employees and their families in Canada.

Under the deal, CloudMD will buy all of the outstanding securities of the target company and will pay HumanaCare shareholders a total of C$17.5 million, of which C$6.3 million will be in cash, C$6.825 million in CloudMD common shares and C$4.375 million as performance-based earnout. The common shares will be issued at a deemed price of C$2.88 apiece.

The acquisition will be immediately accretive to CloudMD, according to the company's Oct. 28 news release.

The acquisition is subject to customary closing conditions, including having a definitive acquisition agreement and approval from the TSX Venture Exchange.

The transaction follows a series of acquisitions that CloudMD has made recently. The company, which provides healthcare software technologies for healthcare providers across North America, signed two separate binding term sheets last week to acquire Medical Confidence Inc. and Canadian Medical Director for C$6 million and C$2 million, respectively.

Earlier in October, the company reported the completion of its acquisition of online mental health services provider Snapclarity Inc. for C$3.4 million.

[tutt1126]

$2.65 by tomorrow

[RDT]

Article - CloudMD (DOC-CSE) is my favourite way to play Tele-Health. It’s growing quickly with over 100,000 patients registered on its app and over 3000 doctors in 8 provinces in its Electronic Medical Records—EMR system. It has MULTIPLE revenue streams and… it just moved into Canada’s largest market—Ontario—setting up an even faster growth rate.

The recent spread of Coronavirus is only accelerating this. COVID-19 has forever changed how we all will think about visiting a hospital or seeing our doctor. We really don’t want to do that at all, if possible. It will have a very positive and long lasting impact on TeleHealth.

https://investingwhisperer.com/cloudmd-doc-cse-docrf-otc-is-my-tele-health-stock/

[KISSINGER]

150 followers? Out of 600 thats 25% in a week. What happened there Trend?

[KISSINGER]

DOCRF chart is not looking good, lack of volume and momentum and a rounding top forming. Perfect for a downdraught.

As far as you telling SYKES he needs to learn how to read a chart you have been wrong 4 x on ATVK inside 3 weeks. In the process you lost over 150 followers.

Please explain why we should listen to you?

[happyglass]

Awesome! Thank you :)

[RDT]

There's a little more action on https://ceo.ca/doc

[happyglass]

Folks like to be where there is more action I guess, I stop by here daily but there is no real news at the moment so nobody has anything to talk about. I agree this company has incredible potential!

[Flo1]

Why so quiet over here? I think this is a real up and comer!

[happyglass]

They just got almost $30 million from Cannacord, that would have the effect of at least boosting confidence. It was at $2.40 so we may stay here until new milestones are announced

[nowwhat2]

AH - Okay - This is what I was lookin' for.....(their entire history)




Instead of only since they began trading on what exchange(s) ?




Broke out at .95-ish cents




Should be reporting any day now I guess.....and the numbers presumedly must be enormously better ?

[nowwhat2]

Hi, hey I've only just now half learnt of them and I'm afraid I just can't see it ;

Oooops - Nevermind - Just took me a while to find this page (which hopefully might help explain things)
https://investors.cloudmd.ca/blog/






Earlier :

Like, is this some kind of joke, or what ?



Certainly there's no doubt a super-demand for it (tele-med) (here in B.C.) and the rest of the country,

So why're their revenues so alarmingly low and - What's their market cap ?




I'll look over this page link - Is there anything in it especially worth noting ? Like say, the/a (recent) US acquisition ?

https://investors.cloudmd.ca/blog/




There's just gotta be a sound reason for this sp appreciation !




Sept 29th ?
https://investors.cloudmd.ca/cloudmd-acquires-majority-interest-in-innovative-u-s-based-provider-of-cloud-based-practice-management-and-electronic-health-records-with-us4-9m-in-sales/



Oct 15th
https://investors.cloudmd.ca/cloudmd-closes-acquisition-of-snapclarity-inc-creating-one-centralized-assessment-oriented-platform-that-provides-access-to-primary-care-and-mental-health/




Just how well have THOSE acquisitions been functioning ?

[tutt1126]

https://www.msn.com/en-US/money/savingandinvesting/hotter-than-shopify-these-2-stocks-are-up-over-300-in-2020/ar-BB1aiBlN?ocid=FinanceShimLayer